CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug

PartnershipPositive
AI Analysis

Summary

CSL agreed to co-develop Alentis Therapeutics' anti-fibrosis drug for kidney and liver disease, paying $355 million upfront with up to $1.2 billion in future milestone payments.

Importance:7/10
Sentiment:
0.70
partnershipco-developmentanti-fibrosiskidney diseaseliver diseasedeal announcement
Related Companies

Read the original article

Published by Endpoints News on October 5, 2026 2:22 AM

Read Original